IDH1-mutant Cholangiocarcinoma
1 clinical trials · Condition
◉ Watch IDH1-mutant Cholangiocarcinoma
| Record | Firm | Date |
|---|---|---|
| Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma (NCT05921760) | Servier Bio-Innovation LLC | 2023-10-23 |
Track IDH1-mutant Cholangiocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.